Janux Therapeutics Q4 EPS $(0.25) Beats $(0.41) Estimate, Sales $2.46M Beat $740.00K Estimate

Janux Therapeutics, Inc. +5.30%

Janux Therapeutics, Inc.

JANX

52.65

+5.30%

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.41) by 39.02 percent. This is a 35.9 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $2.46 million which beat the analyst consensus estimate of $740.00 thousand by 232.57 percent. This is a 13.50 percent decrease over sales of $2.85 million the same period last year.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via